|
Congenital atresia of extrahepatic bile duct
|
0.010 |
Biomarker
|
disease |
BEFREE |
The FGF19 protein was synthesized in BA HET, and its serum concentration was elevated.
|
30156739 |
2019 |
|
Malignant neoplasm of thyroid
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results indicate that a disrupted FGF19/FGFR4/βKL signaling pathway may play a role in the development of thyroid cancers.
|
29438906 |
2018 |
|
Coronary Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Conclusions- A combination of the 3 biomarkers, lipocalin-2, A-FABP, and FGF-19, with clinical risk factors to yield the age-biomarkers-clinical risk factor model provides an optimal and validated prediction of new-onset MACE in patients with stable coronary artery disease.
|
30354221 |
2018 |
|
Coronary heart disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Conclusions- A combination of the 3 biomarkers, lipocalin-2, A-FABP, and FGF-19, with clinical risk factors to yield the age-biomarkers-clinical risk factor model provides an optimal and validated prediction of new-onset MACE in patients with stable coronary artery disease.
|
30354221 |
2018 |
|
Hepatitis, Alcoholic
|
0.010 |
Biomarker
|
disease |
BEFREE |
Univariate analysis demonstrated significant associations between FGF19 and bilirubin as well as gamma glutamyl transferase, and negative correlations between FGF19 and fibrosis stage as well as polymorphonuclear leukocyte infiltration, in all patients with alcoholic hepatitis.
|
29654817 |
2018 |
|
Cerebrovascular accident
|
0.010 |
AlteredExpression
|
group |
BEFREE |
This view is consistent with known physiological role of ACOX1 in yielding precursors of specialized proresolving mediators (SPM) and with characteristics of aging and related disorders including reduced PGC1-<i>α</i> function and improvement by strategies rising ACOX1 (via hormonal gut FGF19 and nordihydroguaiaretic acid in metabolic syndrome and diabetes conditions) and SPM (neurodegenerative disorders, atherosclerosis, and stroke).
|
29765501 |
2018 |
|
Papillary thyroid carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Significantly lower concentrations of βKL and higher concentrations of FGF19 were found in patients with PTC, FTC and ATC as compared with MNG group and controls.
|
29438906 |
2018 |
|
Primary cholangitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
This gut-liver FXR-FGF19 dual action is the paradigm of physiological BA regulation and it is currently targeted in the clinical practice for liver disease such as primary cholangitis.
|
30223181 |
2018 |
|
Progressive intrahepatic cholestasis (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, the recent identification of a new type of genetic progressive familial intrahepatic cholestasis (PFIC) linked to FXR mutations has strengthen also the bona fide beneficial effects of target therapies that by-pass FXR activation, directly promoting the action of its target, namely the enterokine FGF19, in the repression of hepatic BAs synthesis with reduction of total BA levels in the liver and serum, accomplishing one of the major goals in cholestasis.
|
28965883 |
2018 |
|
Thyroid carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results indicate that a disrupted FGF19/FGFR4/βKL signaling pathway may play a role in the development of thyroid cancers.
|
29438906 |
2018 |
|
Mammary Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
FGF19 is particularly highly expressed in luminal molecular subtype of breast tumors and its expression levels are positively associated with its secretion levels from breast cancer cells.
|
30074276 |
2018 |
|
Coronary Artery Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Conclusions- A combination of the 3 biomarkers, lipocalin-2, A-FABP, and FGF-19, with clinical risk factors to yield the age-biomarkers-clinical risk factor model provides an optimal and validated prediction of new-onset MACE in patients with stable coronary artery disease.
|
30354221 |
2018 |
|
Cholestasis, progressive familial intrahepatic 1
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, the recent identification of a new type of genetic progressive familial intrahepatic cholestasis (PFIC) linked to FXR mutations has strengthen also the bona fide beneficial effects of target therapies that by-pass FXR activation, directly promoting the action of its target, namely the enterokine FGF19, in the repression of hepatic BAs synthesis with reduction of total BA levels in the liver and serum, accomplishing one of the major goals in cholestasis.
|
28965883 |
2018 |
|
Intrahepatic Cholestasis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Although FGF19 mRNA is absent in normal liver, FGF19 gene expression was reported to increase in response to both extrahepatic and intrahepatic cholestasis.
|
28570655 |
2017 |
|
Liver Cirrhosis, Alcoholic
|
0.010 |
Biomarker
|
disease |
BEFREE |
Concentrations of zinc and selenium in serum of patients with alcoholic liver cirrhosis are not independently related to concentrations of FGF-19 and ENG.
|
28954507 |
2017 |
|
Functional diarrhea
|
0.010 |
Biomarker
|
disease |
BEFREE |
To analyse prevalence, specificity and reproducibility of fasting C4 and FGF19 in identifying bile acid diarrhoea in patients with irritable bowel syndrome with predominant diarrhoea or functional diarrhoea (summarised as IBS-D).
|
28691284 |
2017 |
|
Adrenocortical carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In 18 evaluable patients with FGFR genetic alterations, 3 confirmed partial responses (two intrahepatic cholangiocarcinomas (iCCA) with FGFR2 fusions and one urothelial cancer with FGFR2 and FGF19 amplification) and two durable stable disease at ⩾16 weeks with tumour reduction (FGFR2 fusion-positive iCCA and adrenocortical carcinoma with FGFR1 amplification) were observed.
|
28972963 |
2017 |
|
Impaired glucose tolerance
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Here we measured six BAs including chenodeoxycholic acid (CDCA), cholic acid, deoxycholic acid, their glycine conjugates and FGF19 levels during oral glucose tolerance test (OGTT) in normal glucose tolerance (NGT), isolated-impaired glucose tolerance, I-IFG, combined glucose intolerance (CGI) and T2DM subjects.
|
28729691 |
2017 |
|
Intrahepatic Cholangiocarcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In 18 evaluable patients with FGFR genetic alterations, 3 confirmed partial responses (two intrahepatic cholangiocarcinomas (iCCA) with FGFR2 fusions and one urothelial cancer with FGFR2 and FGF19 amplification) and two durable stable disease at ⩾16 weeks with tumour reduction (FGFR2 fusion-positive iCCA and adrenocortical carcinoma with FGFR1 amplification) were observed.
|
28972963 |
2017 |
|
Compensated cirrhosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The highest concentration of FGF-19 was found in Child-Pugh stage C liver cirrhosis patients (806.9±650.3 pg/ml), and was significantly higher than observed in controls (p=0.005) and stage A patients (compensated cirrhosis) (p=0.02).
|
28954507 |
2017 |
|
Apert syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Further research is needed to determine the role of modulation of MSC proliferation or use of FGF19 or anti-BMP2 as inhibitors of osteogenesis in AS subjects' cells, and whether these findings can be used in the clinical management of AS.
|
27339175 |
2016 |
|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
FGF19 has been shown to be involved in EMT in cholangiocarcinoma and colorectal cancer, however, molecular mechanisms underlying FGF19-induced EMT process in hepatocellular carcinoma (HCC) remain largely unknown.
|
26498355 |
2016 |
|
Hypertriglyceridemia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
A subgroup of 30% of PBAD patients had fasting hypertriglyceridemia and higher FGF19.
|
26856750 |
2016 |
|
Cholangiocarcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
FGF19 has been shown to be involved in EMT in cholangiocarcinoma and colorectal cancer, however, molecular mechanisms underlying FGF19-induced EMT process in hepatocellular carcinoma (HCC) remain largely unknown.
|
26498355 |
2016 |
|
Posterior subcapsular cataract
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Hepatobiliary tissues of PSC and non-PSC patients (n = 8-11 per patient group) were collected at transplantation and were analysed for IL8 and FGF19 mRNA expression and IL8 localization.
|
26866350 |
2016 |